148 related articles for article (PubMed ID: 27074567)
1. Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.
Ocaña A; Díez-González L; Esparís-Ogando A; Montero JC; Amir E; Pandiella A
Oncotarget; 2016 Jul; 7(29):45042-45051. PubMed ID: 27074567
[TBL] [Abstract][Full Text] [Related]
2. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer.
de Alava E; Ocaña A; Abad M; Montero JC; Esparís-Ogando A; Rodríguez CA; Otero AP; Hernández T; Cruz JJ; Pandiella A
J Clin Oncol; 2007 Jul; 25(19):2656-63. PubMed ID: 17602072
[TBL] [Abstract][Full Text] [Related]
3. HER3 overexpression and survival in solid tumors: a meta-analysis.
Ocana A; Vera-Badillo F; Seruga B; Templeton A; Pandiella A; Amir E
J Natl Cancer Inst; 2013 Feb; 105(4):266-73. PubMed ID: 23221996
[TBL] [Abstract][Full Text] [Related]
4. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
Mendell J; Freeman DJ; Feng W; Hettmann T; Schneider M; Blum S; Ruhe J; Bange J; Nakamaru K; Chen S; Tsuchihashi Z; von Pawel J; Copigneaux C; Beckman RA
EBioMedicine; 2015 Mar; 2(3):264-71. PubMed ID: 26137564
[TBL] [Abstract][Full Text] [Related]
5. Neuregulin-1 and human epidermal growth factor receptors 2 and 3 play a role in human lung development in vitro.
Patel NV; Acarregui MJ; Snyder JM; Klein JM; Sliwkowski MX; Kern JA
Am J Respir Cell Mol Biol; 2000 Apr; 22(4):432-40. PubMed ID: 10745024
[TBL] [Abstract][Full Text] [Related]
6. The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation.
Centa A; Rodríguez-Barrueco R; Montero JC; Pandiella A
Mol Oncol; 2018 Jun; 12(7):1061-1076. PubMed ID: 29683256
[TBL] [Abstract][Full Text] [Related]
7. HER3 expression is correlated to distally located and low-grade colon cancer.
Lédel F; Stenstedt K; Hallström M; Ragnhammar P; Edler D
Acta Oncol; 2016 Jul; 55(7):875-80. PubMed ID: 26863446
[TBL] [Abstract][Full Text] [Related]
8. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of the Metabolic Marker Hexokinase-2 in Various Solid Tumors: A Meta-Analysis.
Liu Y; Wu K; Shi L; Xiang F; Tao K; Wang G
PLoS One; 2016; 11(11):e0166230. PubMed ID: 27824926
[TBL] [Abstract][Full Text] [Related]
10. NRG-1 Stimulates Serum DJ-1 Increase in Breast Cancers.
Wang Y; Zhang Y; Lu Q; Wang Y; Sun X; Zhang S
Pathol Oncol Res; 2019 Jan; 25(1):71-79. PubMed ID: 28963699
[TBL] [Abstract][Full Text] [Related]
11. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
Baselga J; Cortés J; Im SA; Clark E; Ross G; Kiermaier A; Swain SM
J Clin Oncol; 2014 Nov; 32(33):3753-61. PubMed ID: 25332247
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
13. The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer.
McIntyre E; Blackburn E; Brown PJ; Johnson CG; Gullick WJ
Breast Cancer Res Treat; 2010 Jul; 122(1):105-10. PubMed ID: 19760033
[TBL] [Abstract][Full Text] [Related]
14. Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.
Lee CK; Davies L; Gebski VJ; Lord SJ; Di Leo A; Johnston S; Geyer C; Cameron D; Press MF; Ellis C; Loi S; Marschner I; Simes J; de Souza P
J Clin Oncol; 2016 Mar; 34(9):936-44. PubMed ID: 26811533
[TBL] [Abstract][Full Text] [Related]
15. HER3 over-expression and overall survival in gastrointestinal cancers.
Wang Y; Yang H; Duan G
Oncotarget; 2015 Dec; 6(40):42868-78. PubMed ID: 26517355
[TBL] [Abstract][Full Text] [Related]
16. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
19. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer.
Beji A; Horst D; Engel J; Kirchner T; Ullrich A
Clin Cancer Res; 2012 Feb; 18(4):956-68. PubMed ID: 22142822
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
